Race-Specific Differences in Endothelial Function: Predisposition of African Americans to Vascular Diseases
暂无分享,去创建一个
[1] T. Malinski,et al. Cerivastatin potentiates nitric oxide release and enos expression through inhibition of isoprenoids synthesis. , 2002, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[2] A. Dominiczak,et al. NAD(P)H Oxidase Inhibition Improves Endothelial Function in Rat and Human Blood Vessels , 2002, Hypertension.
[3] U. Walter,et al. Effects of Angiotensin II Infusion on the Expression and Function of NAD(P)H Oxidase and Components of Nitric Oxide/cGMP Signaling , 2002, Circulation research.
[4] L. Dobrucki,et al. Increased Nitric Oxide Bioavailability in Endothelial Cells Contributes to the Pleiotropic Effect of Cerivastatin , 2002, Circulation.
[5] M. Stratford,et al. Oxidation of tetrahydrobiopterin by biological radicals and scavenging of the trihydrobiopterin radical by ascorbate. , 2002, Free radical biology & medicine.
[6] R. Cohen,et al. S17834, a New Inhibitor of Cell Adhesion and Atherosclerosis That Targets NADPH Oxidase , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[7] T. Lüscher,et al. Enhanced Peroxynitrite Formation Is Associated with Vascular Aging , 2000, The Journal of experimental medicine.
[8] Y. Xian,et al. Amperometric ultramicrosensors for peroxynitrite detection and its application toward single myocardial cells. , 2000, Analytical chemistry.
[9] K. Channon,et al. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. , 2000, Circulation research.
[10] G. Kojda,et al. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. , 1999, Cardiovascular research.
[11] R. Cannon,et al. Attenuation of cyclic nucleotide-mediated smooth muscle relaxation in blacks as a cause of racial differences in vasodilator function. , 1999, Circulation.
[12] T. Poulos,et al. Crystal Structure of Constitutive Endothelial Nitric Oxide Synthase A Paradigm for Pterin Function Involving a Novel Metal Center , 1998, Cell.
[13] E. Moilanen,et al. Radical releasing properties of nitric oxide donors GEA 3162, SIN-1 and S-nitroso-N-acetylpenicillamine. , 1998, European journal of pharmacology.
[14] E. Werner,et al. Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. , 1998, The Journal of clinical investigation.
[15] U. Losert,et al. L-arginine treatment alters the kinetics of nitric oxide and superoxide release and reduces ischemia/reperfusion injury in skeletal muscle. , 1997, Circulation.
[16] A. Scheeline,et al. Amperometric sensors for simultaneous superoxide and hydrogen peroxide detection. , 1997, Analytical chemistry.
[17] Detection. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) , 1997 .
[18] R. Weinshilboum,et al. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. , 1997, Archives of internal medicine.
[19] S. Snyder,et al. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[20] S. Moncada,et al. Direct measurement of nitric oxide in human beings , 1995, The Lancet.
[21] P Whelton,et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. , 1995, Hypertension.
[22] T. Malinski,et al. Nitric oxide release from a single cell measured in situ by a porphyrinic-based microsensor , 1992, Nature.
[23] T. Malinski,et al. Conductive polymeric porphyrin films: application in the electrocatalytic oxidation of hydrazine , 1991 .
[24] J. Fleiss,et al. Some Statistical Methods Useful in Circulation Research , 1980, Circulation research.